Quince Therapeutics, Inc. (QNCX) Free cash flow 2018–2025
Quince Therapeutics, Inc. (QNCX) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$41.8MFY2025 · since FY2018: -$11.9M → -$41.8M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$41.8M | -29.9% |
| FY2024 | -$32.2M | -74.3% |
| FY2023 | -$18.5M | +58.2% |
| FY2022 | -$44.2M | +30.0% |
| FY2021 | -$63.1M | -24.1% |
| FY2020 | -$50.9M | -52.6% |
| FY2019 | -$33.3M | -179.9% |
| FY2018 | -$11.9M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More QNCX financial trends
QNCX RevenueQNCX Net incomeQNCX Net marginQNCX Gross profitQNCX Gross marginQNCX Operating incomeQNCX Operating marginQNCX Operating cash flowQNCX Capital expendituresQNCX Return on equityQNCX Stock buybacksQNCX Dividends paidQNCX Total assetsQNCX Total liabilitiesQNCX Shareholders’ equityQNCX overview →